ABT-737 activates caspase-3. Platelets were treated with ABT-737 (10 µM) or dimethyl sulfoxide (DMSO) (vehicle, as control) for the times indicated. Asterisks indicate cleavage products. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. The blots are representative of 5 independent experiments.
ABT-737 triggers cytochrome c release from mitochondria and loss of mitochondrial membrane potential. (A) Platelets were treated with QVD-Oph where indicated (or dimethyl sulfoxide [DMSO] vehicle as control) and then with ABT-737 (10 µM) for 10 or 30 minutes. Platelets were briefly permeabilized with digitonin (0.05 % w/v, 2 minutes) and the cytosol-rich fraction removed by centrifugation. The digitonin-resistant pellet shows loss of the cytosol marker, extracellular signal-regulated kinases 1 and 2 (ERK1/2), but retained the mitochondrial marker, COX IV. (B) Platelets loaded with trimetylrhodamine methyl ester (TMRM), treated with the drugs indicated then with ABT-737 (10 µM) for the time indicated. The blots are representative of 5 independent experiments.
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